According to a new, phase 2 clinical trial led by Dana-Farber Cancer Institute doctors, a three-medicine combination that drove chronic lymphocytic leukaemia (CLL) patients into profound remissions in a clinical study is very beneficial in patients with high-risk variants of the disease.
New Delhi [India], February 11 (ANI/NewsVoir): To commemorate World Cancer Day observed each year on 4th February, Life Sciences-Biosciences, a segment of BD (Becton, Dickinson and Company) organized a virtual clinical user group meeting on "Conceptual and practical aspects of validating 10+ color MRD assay" in sync with the theme of world cancer day of this year "Closing the Care Gap".
\
\
\
\
